These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8420208)

  • 1. Protective effect of selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early combination with deprenyl: a retrospective analysis.
    Fornadi F; Ulm G
    Adv Neurol; 1990; 53():437-40. PubMed ID: 2122650
    [No Abstract]   [Full Text] [Related]  

  • 4. [Stage-adjusted treatment of idiopathic Parkinson syndrome].
    Ludin HP
    Wien Med Wochenschr; 1995; 145(13):294-8. PubMed ID: 7571654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan.
    Montastruc JL; Fabre N; Rascol O; Senard JM; Blin O
    Mov Disord; 1994 Mar; 9(2):242-3. PubMed ID: 8196695
    [No Abstract]   [Full Text] [Related]  

  • 7. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Adv Neurol; 1990; 53():431-5. PubMed ID: 2122649
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy of parkinsonism with deprenyl.
    Behari M; Ahuja GK; Singh K; Prasad K
    J Assoc Physicians India; 1992 Jun; 40(6):365-7. PubMed ID: 1452557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
    Olanow CW; Godbold JH; Koller W
    BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
    [No Abstract]   [Full Text] [Related]  

  • 11. Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the Collaborative European Multicentric Trial.
    Olsson JE
    Adv Neurol; 1990; 53():421-3. PubMed ID: 2239483
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
    Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
    [No Abstract]   [Full Text] [Related]  

  • 13. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of selegiline as initial monotherapy in early Parkinson's disease.
    Bhatia M; Jain S; Maheshwari MC
    J Assoc Physicians India; 1994 Jan; 42(1):30-2. PubMed ID: 7836244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
    Stryjer R; Klein C; Treves TA; Rabey JM
    Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease in the elderly: current management strategies.
    Aminoff MJ
    Geriatrics; 1987 Jul; 42(7):31-7. PubMed ID: 3110015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease.
    Factor SA
    Mov Disord; 1993 Apr; 8(2):240-1. PubMed ID: 8474504
    [No Abstract]   [Full Text] [Related]  

  • 18. Selegiline, fluoxetine, and depression in Parkinson's disease.
    Garcia-Monco JC; Padierna A; Gomez Beldarrain M
    Mov Disord; 1995 May; 10(3):352. PubMed ID: 7651457
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
    MacMahon DG; Bland R
    BMJ; 1996 Mar; 312(7032):703; author reply 704-5. PubMed ID: 8597748
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Parkinson's disease.
    Bergus G
    J Fam Pract; 1996 May; 42(5):457-8. PubMed ID: 8642360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.